Drugs / Low-Dose Naltrexone
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06366724 Comparator | Sep 2024 → Sep 2026 overdue | long COVID-19, myalgic encephalomeyelitis/chronic fatigue syndrome | Brigham and Women's Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Low-Dose Naltrexone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06366724 ↗ |